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Recombinant Bacillus Calmette-Gu´ erin (rBCG) strain is the promising vaccine candidate for tuberculosis (TB) prevention, which
aims at providing more enduring and enhanced protection than the parental BCG vaccine. In this study, three rBCG strains
overexpressing immunodominant antigens Ag85B (rBCG::85B), Ag85A (rBCG::85A), or both (rBCG::AB) of Mycobacterium
tuberculosis were constructed, respectively. rBCG strains showed higher level of overexpression of Ag85A and/or Ag85B proteins
than BCG containing empty vector pMV261(rBCG::261), which had low levels of endogenous expression of both proteins as
expected. rBCG::AB strain could provide the strongest short-term and long-term protection in the lung against intravenous
infection with virulent M. tuberculosis than rBCG::261 control and other two rBCG strains overexpressing single antigen. The
strongerandlonger-lastingprotectionprovidedbyrBCG::ABthanrBCG::261wascorrelatedwithsystemicinvitroantigen-speciﬁc
IFN-γ responses. Therefore, our results indicate that rBCG::AB could be a very promising TB vaccine candidate and should be
further evaluated for the preclinical test.
1.Introduction
Tuberculosis (TB) is the second leading infectious cause of
mortalityworldwide.AlthoughMycobacteriumbovisBacillus
Calmette-Gu´ erin (BCG) vaccine is eﬀective in children
against miliary and meningeal TB, it provides variable pro-
tection against pulmonary TB in adults, because BCG only
confers protection for 5–10 years following the neonatal vac-
cination and is not eﬀective for inducing long-term cellular-
mediated immunity (CMI) and protection [1]. Therefore,
BCG in its current form is not a satisfactory vaccine for TB
and new vaccines are urgently needed.
One important strategy in designing new TB vaccines is
to develop recombinant BCG (rBCG) strains overexpressing
M. tuberculosis antigens, which might stimulate more potent
immune responses against M. tuberculosis infection and
conferring more enduring protection than BCG vaccination.
rBCG strains, which have been genetically manipulated to
overexpress immunodominant antigens of M. tuberculosis,
are promising vaccine candidates in this area, such as the
rBCG strains overexpressing protective antigens Ag85B [2–
5], Ag85A [6–8], Ag85C [9], ESAT-6 [10–13], or HspX [14],
respectively. Moreover, these rBCG strains showed better
protective eﬃcacy than the parent BCG vaccine in experi-
mental animal models of TB.
During the past decades, animals vaccinated with DNA
or subunit vaccines based on multiple antigens showed more
potent eﬀects of preventing against M.tuberculosis infection
than those with single antigen alone [15–19]. rBCG strain
overexpressing the fusion protein of multiple antigens also
would lead to increased protection against M. tuberculosis
infection [20–25]. In the present study, we constructed an
rBCGstrainoverexpressingantigensbothAg85AandAg85B,
and assessed its immunogenicity and protective eﬃcacy as a
vaccine against M. tuberculosis infection in mice.
2.MaterialsandMethods
2.1.BacterialStrainsandCultures. EscherichiacoliDH5αand
BL21 (DE3) strains were grown in Luria-Bertani medium2 Clinical and Developmental Immunology
and used for cloning and expression, respectively. M. bovis
BCG China (obtained from Shanghai Institute of Biological
Products which is the main manufacturer of BCG vaccine in
China), M. tuberculosis H37Rv and rBCG strains were grown
in either Middlebrook 7H9 medium (Difco Laboratories,
Detroit, MI) or on Middlebrook 7H11 agar (Difco Labo-
ratories), supplemented with 10% ADC, 0.5% glycerol and
0.05% Tween 80. When required, kanamycin or ampicillin
wasaddedataﬁnalconcentrationof25μg/mLor100μg/mL,
respectively.
2.2.OverexpressionofRecombinantAg85AandAg85BProteins
in E. coli . Recombinant Ag85A and Ag85B proteins were
produced as described previously [14, 26]. Brieﬂy, both fbpA
and fbpB without their signal peptide sequences were cloned
into pProExHTb (Life Technologies, Rockville, MD, USA)
and constructed as recombinant plasmids pPro85A and
pPro85B, respectively. Both Ag85A and Ag85B proteins with
N-terminal HIS6 tag were expressed from E. coli BL21 (DE3)
strains harboring recombinant plasmids and then puriﬁed
on an Ni-NTA column (Life Technologies) according to the
manufacturer’s instructions, lyophilized and conﬁrmed by
Western blotting. Both proteins were diluted in phosphate-
buﬀered saline (PBS) using pyrogen-free reagents and stored
at −20◦C. Endotoxin contamination and protein concentra-
tion were determined as described previously [14].
2.3. Construction of rBCG Strains. Two recombinant BCG
strains, rBCG::85B (overexpressing antigen Ag85B) and
rBCG::261 (containing empty vector pMV261), were pro-
duced as described previously [14]. The full length sequence
for fbpA (about 1.8kb) was ampliﬁed by PCR from M.
tuberculosis H37Rv genomic DNA. pMAg85A was created by
cloning PCR-ampliﬁed fbpA into the pcDNA3.1(−)v e c t o r
and then subcloned into the pMV261 vector. pMAg85AB
was further constructed by subcloning fbpB from pMAg85B
into pMAg85A. Each gene was expressed from its own pro-
moters and targeted the expressed protein for secretion
through their own signal peptide sequences. Recombinant
plasmids ampliﬁed in E. coli DH5α were transformed into
BCG by electroporation. Kanamycin-resistant colonies were
selected and grown in Middlebrook 7H9 broth. Culture
supernatants from cultures that had reached an optical
density at 600nm of 1.0 were harvested after centrifugation
and passage through a 0.22μm pore-size ﬁlter. Samples from
supernatants were concentrated approximately 50-fold by
freeze drying. Cell pellets were washed, resuspended in PBS
with the equivalent values of cell density, and disrupted on
ice with an Ultrasonic Processor. The bacterial cell debris
from the sonicated samples was removed by centrifugation.
About 40μg proteins of bacterial pellets or supernatants
were separated by SDS-PAGE on a 12.5% gel and then
analyzed by Western blotting. Total proteins were then trans-
ferred onto a nitrocellulose membrane. The membrane was
saturated with 1% bovine serum albumin (BSA) in PBS—
0.1% Tween 20 (PBST) and then incubated with anti-Ag85A
chicken polyclonal antibody (diluted 1/2000; ab14073,
Abcam, UK) or anti-Ag85B rabbit polyclonal antibody
(diluted 1/2000; ab43019, Abcam, UK). Goat anti-chicken
HRP-conjugated antibodies (Biosynthesis Biotech. Co. LTD,
Beijing, China) or goat anti-rabbit HRP-conjugated anti-
bodies (Zhongshan Goldenbridge Biotech. Co. LTD, Beijing,
China) diluted 1/5000 in PBST were then used to develop
the immunoblots as described [14]. The positive plasmid
constructs rBCG::85A and rBCG::AB were also sequenced.
The anticipated sequences of the inserts were conﬁrmed.
2.4. Mice and Immunization Protocol. Animal experiments
were performed in accordance with the guidelines of Chi-
nese Council on Animal Care. The research protocol was
approvedbyTongjiMedicalSchoolCommitteesonBiosaftey.
Speciﬁc pathogen-free, female C57BL/6 mice at 6 weeks of
age (Beijing Vital River Com., Beijing, China) were bred in
separate cages in a biosafety laboratory and fed commercial
mouse chow and water ad libitum. Twenty-two mice in each
group were immunized s.c. once at the base of the tail with
1 × 106 CFU of either rBCG::85A, rBCG::85B, or rBCG::AB
in a ﬁnal volume of 100μL of PBS. Two control groups were
immunized with rBCG::261 or treated with 100μL of PBS,
respectively. Six mice were sacriﬁced for the immunological
assay after 6 or 24 weeks. Other mice were challenged with
virulent M. tuberculosis strain 6 weeks after immunization
and 5 mice were used for bacterial load in organs and
pathological analysis at 10 and 24 weeks, respectively. All
experiments were performed as in Figure 3 and repeated
three times.
2.5. Antigen-Speciﬁc IgG Assay. Antigen-speciﬁc IgG anti-
bodyintheserumofeachmousewasdeterminedbyenzyme-
linked immunosorbent assay (ELISA). ELISA plates were
coated overnight at 4◦C with 100μL either Ag85B, Ag85A
orantigencontrol(5μg/mL)incarbonate/bicarbonatebuﬀer
(pH 9.6). The plates were blocked with 200μL/well PBS
containing 1% bovine serum albumin for 30min at 37◦C
and washed with PBS containing 0.05% Tween 20 ﬁve times.
Individual serum samples were added at serial two-fold
dilutions (beginning at a 1/500 dilution) and incubated for
2hat37 ◦C and washed, followed by addition of 100μL/well
horseradish peroxidase-conjugated rabbit anti-mouse IgG
(diluted at 1/5000). Plates were incubated for 1h at 37◦C,
washed and developed with 3, 3 5, 5 -Tetramethylbenzidine
(TMB) substrate. Reactions were stopped by addition of
50μL/well of 1N H2SO4 a n dw e r er e a do na nE L I S Ap l a t e
reader at 450nm. The OD value from antigen control
was subtracted as background to exclude antibody against
nonspeciﬁc E. coli protein. Sera from mice group treated
with PBS were used as the negative control (N). Sera with
P/N value ≥2.1 were considered positive. Antibody titers
were expressed as reciprocal end point titers and results were
showed as the mean of log2 antibody titer of each vaccinated
group.
2.6. IFN-γ Enzyme-Linked Immunospot (ELISPOT) Assay.
Six and 24 weeks after C57BL/6 mice were vaccinated,
the mouse IFN-γ ELISPOT kit (U-CyTech biosciences,
Netherlands) was used to determine the number of IFN-γ
expressing cells in the single-cell spleen suspensions fol-
lowing the manufacturer’s instructions. Lymphocytes fromClinical and Developmental Immunology 3
spleenofthreemouseineachgroupwerepreparedusingEZ-
Sep Mouse 1 × Lymphocyte Separation Medium (Dakewe
Biotech Com., Shenzhen, China) according to the manu-
facturer’s recommendations. The cells were diluted to a
concentration of 2.5 × 106/mL with Lympho-Spot serum-
free medium for rodent (Dakewe Biotech Com.) containing
anappropriatestimulus(2μg/wellofPPD,Ag85AorAg85B).
2.5 ×105 cells were added to the wells of the ELISPOT plate.
IFN-γ spot-forming cells (SFCs) were enumerated using an
ELISPOT Reader (Biosys Bioreader 4000PRO). For each
animal, the number of spots in wells with medium alone
was subtracted from the number of spots in test wells. The
mean number of antigen-speciﬁc IFN-γ spot-forming cells
per million cells for each group was determined.
2.7. Challenge of Mice with Virulent M. tuberculosis H37Rv.
Six weeks after immunization, ten C57BL/6 mice in each
groupwerechallengedbytheinjectionof106 CFUofvirulent
M. tuberculosis H37Rv through a lateral tail vein. Four
weeks after challenge, ﬁve mice per group were sacriﬁced for
eﬃcacy comparison and the remainder of infected C57BL/6
mice were kept up to 18 weeks for observation of long-term
protection. The spleens and lungs were removed aseptically,
homogenized, and cultured for CFU of M. tuberculosis on
Middlebrook 7H11 agar containing 2μg/mL of 2-thiophe-
necarboxylic acid hydrazide (TCH, Beijing Luqiao Corp.,
Beijing, China) to selectively inhibit the growth of the resid-
ual BCG.
2.8. Histopathological Analysis. Four weeks and 18 weeks
after the challenge infection, left lung lobes from diﬀerent
vaccine groups were ﬁxed in 10% formalin in PBS and
embedded in paraﬃn. Tissue sections were prepared and
stained with hematoxylin and eosin (HE) stain and acid-
fast stain. The results of pathological changes were recorded
by a pathologist with no prior knowledge for the treatment
groups under a light microscope.
2.9. Statistical Analysis. Student’s t-test was used to compare
the diﬀerence between groups and the diﬀerence was consid-
ered statistically signiﬁcant when the P value was less than
0.05.
3. Results
3.1. Puriﬁcation of Recombinant Ag85A and Ag85B Proteins.
Prokaryotic expression plasmids pPro85A and pPro85B
were shown as Figure 1(a). DNA sequencing and enzyme
digestion conﬁrmed the successful constructions. E. coli
BL21 (DE3) strains containing plasmid pPro85A or pPro85B
were induced with IPTG and puriﬁed on a Ni-NTA column,
respectively. The ﬁnal puriﬁed products of recombinant
proteinsAg85A(32kDa)andAg85B(30kDa)wereidentiﬁed
by 12% SDS-PAGE as expected (Figure 1(b)).
3.2. Construction and Overexpression of Ag85A and Ag85B
Proteins from rBCG Strains. Recombinant Mycobacterium—
E. coli shuttle plasmids pMAg85A and pMAg85AB were
constructed as in Figure 2(a). Two rBCG strains, rBCG::85A
and rBCG::85AB, were obtained by transformation of BCG
with the recombinant plasmids pMAg85A and pMAg85AB,
respectively. The overexpression of proteins in both culture
supernatants and cell lysates of rBCG strains was analyzed
by Western blotting (Figure 2(b)). As expected, low levels of
Ag85A and Ag85B proteins were detected in empty vector
control rBCG261 strain because of endogenous expression.
Ag85A protein was mainly found in the culture supernatant
and cell lysate of rBCG::85A and rBCG::AB strains and
had a much higher concentration than those of rBCG:85B
or rBCG:261 strains. rBCG::AB and rBCG::85B strains
produced much more Ag85B protein in the cell lysate than
rBCG::85A and rBCG:261 strains. In addition, rBCG::85A
also secreted more Ag85B protein in the culture supernatant
with uncertain mechanism than rBCG::85B, whatever anti-
Ag85A or anti-Ag85B serum was used to detect.
3.3. Antibody Responses Induced by rBCG Strains. Antibody
responses against the recombinant puriﬁed Ag85A or Ag85B
protein were evaluated by ELISA in the sera of mice from
diﬀerent groups after 6 and 24 weeks, respectively (Figure 4).
The antibody titers of the PBS control group were negative
(data not shown). Mice vaccinated with diﬀerent rBCG
strains induced higher levels of antibody against Ag85A or
Ag85B protein and IgG antibody titers increased gradually
during the 6–24 weeks. rBCG::AB produced the highest
antibody titres against Ag85A protein among all groups and
much higher than both rBCG::85B and rBCG::261 strains at
6a n d2 4w e e k s( P<0.05). rBCG::AB also produced higher
antibody titres against Ag85B than both rBCG::85A and
rBCG::261 strains at 6 and 24 weeks (P<0.05).
3.4. IFN-γ ELISPOT Assay. Splenocytes were isolated from
mice immunized with rBCG strains following stimulation
with puriﬁed Ag85B, Ag85A, or PPD, respectively (Figure 5).
Splenocytes from PBS control group only produced very low
number of IFN-γ secreted cells during the whole experimen-
tal period, whatever stimulated with PPD, Ag85A, or Ag85B
proteins. Larger number of IFN-γ secreted cells was induced
in mice vaccinated with diﬀerent rBCG strains at 24 weeks
than 6 week after immunization (P<0.05). Upon stim-
ulation with PPD, splenocytes from mice vaccinated with
rBCG::AB produced the highest levels of IFN-γ than other
groups at 6 and 24 weeks (P<0.05). When stimulated
with Ag85A, the number of IFN-γ secreted cells increased
signiﬁcantly in both rBCG::85A and rBCG::AB groups,
which was much more than rBCG::261 and rBCG::85B
groups at 6 and 24 weeks (P<0.05). The highest number
of IFN-γ secreting cells was from rBCG::AB group when
Ag85A protein used (P<0.05) (Figure 5). Both rBCG::AB
and rBCG::85B groups also induced higher level of IFN-γ
responses to Ag85B than rBCG::261 and rBCG::85A groups
at 6 and 24 weeks (P<0.05).
3.5. Protective Eﬃcacy of rBCG Strains. Six weeks after
immunization, C57BL/6 mice were challenged with virulent
M. tuberculosis strain, in order to determine the protective
eﬃcacy of diﬀerent vaccines. Four weeks later, mice were
killedandbacterialloadinthelungandspleenofeachmouse4 Clinical and Developmental Immunology
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Figure 1: Recombinant prokaryotic expression plasmids pPro85A and pPro85B (a) and the puriﬁcation of recombinant Ag85A and Ag85B
proteins (b). The ﬁnal products of recombinant Ag85A and Ag85B proteins were conﬁrmed by SDS-PAGE and stained with a Coomassie
blue dye. Lane M, protein molecular size marker (kDa); lane 1, the ﬁnal products of Ag85A (32kDa); lane 2, the ﬁnal products of Ag85B
(30kDa).
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Figure 2: Recombinant Mycobacterium—E. coli shuttle plasmids (a) and expression of rBCG strains (b). The full-length copies of the M.
tuberculosis fbpA(1.8kb) or fbpB(1.5kb) gene and its ﬂanking regions including the promoter region were ampliﬁed from M. tuberculosis
H37Rv chromosomal DNA, respectively. PCR products were digested by diﬀerent enzymes and cloned into the Mycobacterium—E. coli
shuttle vector pMV261. Ag85A and Ag85B proteins in the cell lysates and supernatants of rBCG::261, rBCG::85B, rBCG::85A, and rBCG::AB
were detected by Western blotting analysis with anti-Ag85A or anti-Ag85B sera, respectively.
was analyzed. A challenge led to the highest bacterial load
in the lung and spleen in PBS control animals (Figure 6).
Vaccination with diﬀerent rBCG strains strongly reduced
b a c t e r i a ll o a di nt h el u n ga n ds p l e e ni nC 5 7 B L / 6m i c e .
rBCG::AB resulted in the most signiﬁcant decrease of the
bacterial load in the lung (P<0.05), when compared
with other three rBCG strains vaccinated mice at both 4
and 18 weeks after infection. Moreover, bacterial load of
M. tuberculosis in lung tissue of rBCG::AB group at 18
week also decreased when compared with that of 4 weeks
after infection. rBCG::AB also inhibited the growth of M.
tuberculosis more signiﬁcantly in the spleen than rBCG::261
vaccinatedC57BL/6miceat4weeksafterinfection.However,
there was no statistical diﬀerence in bacterial load in spleen
of all rBCG vaccinated C57BL/6 mice at 18 week.
3.6. Evaluation of Pathological Changes in Lung Tissue.
Lung tissue from diﬀerent groups of C57BL/6 mice was
ﬁxed, sectioned, and stained with HE stain for assessment
of pathological changes (Figure 7). Four weeks after the
challenge infection, there were the most extensive serious
pathological changes in the lung from mice of PBS controlClinical and Developmental Immunology 5
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Figure 3: Experimental regimens used for both short-term and long-term immunological and protection studies in mice.
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Figure 4: IgG antibodies against Ag85A or Ag85B in mice immunized with rBCG strains (n = 6). Sera were collected from each mice
immunized with diﬀerent rBCG strains at 6 and 24 weeks after immunization. Shown is the mean ± SEM log2 antibody titre per group.
This experiment was repeated with similar results. At 6w, rBCG::85A versus rBCG::261, rBCG::AB versus rBCG::261 with a P<0.05 in anti-
Ag85A IgG antibodies; rBCG::85B versus rBCG::261, rBCG::AB versus rBCG::261 with a P<0.05 in anti-Ag85B IgG antibodies. At 24w,
rBCG::85B versus rBCG::261, rBCG::85A versus rBCG::261, and rBCG::AB versus rBCG::261 with a P<0.05 in anti-Ag85A IgG antibodies;
rBCG::85B versus rBCG::261, rBCG::AB versus rBCG::261 with a P<0.05 in anti-Ag85B IgG antibodies. All groups induced higher levels of
antibodies at 24 weeks than those did at 6 weeks (P<0.05).
group, which showed severe interstitial pneumonia and
intense inﬂammation throughout the lung. Eighteen weeks
later, the largest number of granuloma-like changes was
found in the lung section from PBS control mice. More
seriouspathologicalchangeswithinterstitialpneumoniaand
intense inﬂammation were also observed in the lung from
rBCG::261, rBCG::85A, and rBCG::85B vaccinated groups
at 4 weeks after infection than at 18 week after challenge.
Comparatively, pathological changes were much less in the
lung from mice vaccinated with rBCG::AB, which appeared
to be intact with very limited lung inﬂammation at 4 or 18
week after infection. The result of acid-fast staining of lung
tissue also supported the clear hierarchy of bacterial load in
lung of diﬀerent treated mice.
4. Discussion
Although BCG vaccine has been used to prevent against
human TB since 1921, its eﬃcacy is highly variable in pro-
tection against adult pulmonary TB [27]. Development of a
newvaccinewithasuperiorprotectionoverBCGhasbecome
essential and urgent. Up to now, eleven vaccine regimens,
including two recombinant BCG strains (rBCG30 over-
expressing Ag85B and rBCG UreC:Hly), have progressed in
diﬀerent stages of human clinical trials [28]. rBCG candidate
vaccinesshouldinducemorelong-lastingprotectionthanthe
parent BCG against TB, thus providing stronger protection
to the adult after neonatal vaccination. In this study,
we constructed the recombinant BCG strain (rBCG::AB)6 Clinical and Developmental Immunology
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Figure 5: Interferon (IFN)-g secretion was measured in an ELISPOT assay with splenocytes isolated from C57BL/6 mice immunized with
diﬀerent rBCG strains after 6 and 24 weeks (n = 3). Freshly isolated spleen cells were plated in duplicate at 2.5 × 105 cells per well and
incubated with 2μg/well of PPD, Ag85B, Ag85A, or culture medium control for 72h at 37◦C, 5% CO2, respectively. Results are expressed
as the mean (±SD). This experiment was repeated with similar results. There was statistic diﬀerence between all groups with diﬀerent
stimulations (P<0.05) except rBCG::85B versus rBCG::261 with PPD stimulation at 6 and 24 weeks.
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Figure 6:BacterialloadsperlungandspleeninC57BL/6miceat4and18weeksafterchallenge.Sixweeksafterimmunization,C57BL/6mice
(n = 5) were challenged i.v. with 106 CFU virulent M. tuberculosis H37Rv strain. Four and eighteen weeks after challenge, spleens and lungs
wereharvestedandnumbersofCFUperorganwereenumerated.Resultsareshownasthemean(±SEM)log10CFU/organ.Thisexperiment
was repeated with similar results. At 4w after challenge, PBS versus rBCG::261, rBCG::AB versus rBCG::261, and all other groups (except
rBCG::AB) versus rBCG::AB with a P<0.05 in lung bacterial load; PBS versus rBCG::AB, rBCG::261 versus rBCG::AB, and all other groups
(except rBCG::261) versus rBCG::261 with a P<0.05 in spleen bacterial load. At 18w after challenge, PBS versus rBCG::261, rBCG::85B
versus rBCG::261, rBCG::AB versus rBCG::261, and all other groups (except rBCG::AB) versus rBCG::AB with a P<0.05 in lung bacterial
load; only PBS versus rBCG::261 and PBS versus rBCG::AB with a P<0.05 in spleen bacterial load.Clinical and Developmental Immunology 7
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Figure 7: Representative lung pathology of C57BL/6 mice after
challenge. Vaccinated C57BL/6 mice were challenged i.v. with 106
CFU virulent M. tuberculosis H37Rv strain. Four and 18 weeks after
infection, lung tissue sections from diﬀerent vaccine groups were
prepared for HE staining (×40).
overexpressing the important immunodominant antigens
both Ag85A and Ag85B of M. tuberculosis and evaluated the
immunogenicity and protective eﬃcacy of rBCG::AB in
mice. Our study demonstrated that rBCG::AB strain could
provide the most signiﬁcant enhanced and enduring pro-
tection against virulent M. tuberculosis infection than the
parental BCG vaccine, or rBCG strains overexpressing single
antigen Ag85B or Ag85A alone, as evidenced by the lowest
bacterial load in lung tissue and the lest change in lung
pathology after short-term or long-term challenge infection
with virulent M. tuberculosis. Thus, it is clear that BCG
overexpressing of multiple antigens could provide more en-
hanced protective eﬃcacy than BCG only overexpressing
single antigen.
Many factors could inﬂuence the eﬃcacy of recombinant
BCG strains [29]. On the one hand, identiﬁcation of prom-
ising antigen candidates for rBCG construction plays a
critical role. Not all antigens, conﬁrmed by DNA vaccination
or other vaccine forms, functioned the same by recombinant
BCGtechnology,suchas19kDa[30,31]and27kDalipopro-
tein [32]. Previously, our and others studies demonstrated
that DNA vaccines encoding Ag85A or Ag85B could provide
a certain degree of protection against TB in mouse model
[26, 33] and both antigens can be considered as the most
promising candidate antigens for future TB vaccine devel-
opment. Consistent with the previous report of rBCG30 [2–
5], rBCG::85B overexpressing antigen Ag85B could inhibit
the growth of M. tuberculosis in the lung more signiﬁcantly
than rBCG::261 18 weeks after challenge. The growth of M.
tuberculosis in the lung was inhibited signiﬁcantly in mice
vaccinated with rBCG::85A overexpressing antigen Ag85A.
Moreover, rBCG::85A also conferred the more signiﬁcant
protection in the spleen than rBCG::261 4 weeks after chal-
lenge. Therefore, our results have demonstrated that both
antigens Ag85A and Ag85B might be suitable for vaccine
candidates for enhancing immunogenicity and protective
eﬃcacy of BCG against virulent M. tuberculosis challenge in
humans.
On the other hand, the methods for antigen expression
in BCG also could inﬂuence the eﬃcacy of rBCG candidate
vaccines. Recombinant BCG secreting ESAT-6 strain, under
Hsp60 promoter and Ag85B signal peptide, was found to
provide no enhanced protection compared with the parental
BCG [34] .H o w e v e r ,w h e na r r a n g e da n ds e c r e t e di ni t s
nativeform,ESAT-6secretingrecombinantBCGstraincould
provide more signiﬁcant protection [35]. Both antigens
Ag85A and Ag85B are the major secreted proteins in the
culture ﬁltrates of M. tuberculosis or BCG [36]. In this study,
when the full-length sequences of fbpA or fbpB (including
the ﬂanking regulatory, promoter and signal peptide and
mature peptide sequences) were cloned into the BCG, we
conﬁrmed that overexpression of Ag85A and Ag85B was
secreted on the cell wall and in the culture supernatants of
rBCG::AB strain. Antigen expressed secreted or linked to the
mycobacterial cell membrane by BCG cells has been con-
ﬁrmedwhichcouldinﬂuenceboththetimingoftheimmune
response and the pathway by which antigen is presented
to the immune system [29]. The presentation pathways,
for example, via the MHC class II presentation pathway,
determined the nature of the subsequent cellular and
humoral immune responses induced by rBCG. CD4+ T
cells and IFN-γ responses are important components of
protection against M. tuberculosis [37–39]. After rBCG::AB
immunization, Ag85A and Ag85B antigen-speciﬁc IFN-γ
secreting splenocytes were signiﬁcantly increased and more
cells were produced than those of rBCG::261 or rBCG strains
overexpressing single protein during the entire period, which
may contribute to the enhanced and enduring protection.
Screening and evaluating more immunodominant antigens
by recombinant BCG technology will facilitate the rational
design of rBCG vaccine for TB prevention.
5. Conclusion
In this study, our results demonstrated the vaccination
of C57BL/6 mice with rBCG::AB overexpressing proteins
Ag85A and Ag85B could result in the most signiﬁcant
protection against challenge with virulent M. tuberculosis
H37Rv when compared with rBCG::261, rBCG::85A, or
rBCG::85B alone. Thus, our study indicates that rBCG::AB8 Clinical and Developmental Immunology
may be a promising vaccine candidate against TB and should
be used for the further preclinical test.
Authors’ Contribution
C. Wang, R. Fu, and Z. Chen contributed equally to this
work.
Acknowledgments
This work was supported by grants of the National High
Technology Research and Development of China (863 Pro-
gram no. 2006AA02Z445), the National Mega-projects of
ScienceResearchforthe11thFive-YearPlan(2008ZX-10003-
013), and the Important National Science & Technology
Speciﬁc Projects (2009ZX09301-014).
References
[1] P. Andersen and T. M. Doherty, “The success and failure of
BCG—implications for a novel tuberculosis vaccine,” Nature
Reviews Microbiology, vol. 3, no. 8, pp. 656–662, 2005.
[ 2 ]M .A .H o r w i t z ,G .H a r t h ,B .J .D i l l o n ,a n dS .M a s l e s a - G a l i c ,
“Recombinant bacillus Calmette-Guerin (BCG) vaccines ex-
pressing the Mycobacterium tuberculosis 30-kDa major secre-
toryproteininducegreaterprotectiveimmunityagaintstuber-
culosisthanconventionalBCGvaccines inahighlysusceptible
animalmodel,” ProceedingsoftheNationalAcademyofSciences
of the United States of America, vol. 97, no. 25, pp. 13853–
13858, 2000.
[ 3 ]M .A .H o r w i t z ,G .H a r t h ,B .J .D i l l o n ,a n dS .M a s l e ˇ sa-Gali´ c,
“Extraordinarily few organisms of a live recombinant BCG
vaccine against tuberculosis induce maximal cell-mediated
and protective immunity,” Vaccine, vol. 24, no. 4, pp. 443–451,
2006.
[ 4 ] M .A .H o rwi t z ,G .H a rt h ,B .J .D i l l o n ,a n dS .M a s l eˇ sa-Gali´ c, “A
novel live recombinant mycobacterial vaccine against bovine
tuberculosis more potent than BCG,” Vaccine, vol. 24, no. 10,
pp. 1593–1600, 2006.
[5] M. A. Horwitz and G. Harth, “A new vaccine against tubercu-
losis aﬀords greater survival after challenge than the current
vaccine in the guinea pig model of pulmonary tuberculosis,”
Infection and Immunity, vol. 71, no. 4, pp. 1672–1679, 2003.
[6] I. Sugawara, Z. Li, L. Sun, T. Udagawa, and T. Taniyama,
“Recombinant BCG Tokyo (Ag85A) protects cynomolgus
monkeys (Macaca fascicularis) infected with H37Rv Mycobac-
terium tuberculosis,” Tuberculosis, vol. 87, no. 6, pp. 518–525,
2007.
[7] I. Sugawara, T. Udagawa, and T. Taniyama, “Protective eﬃcacy
of recombinant (Ag85A) BCG Tokyo with Ag85A peptide
boosting against Mycobacterium tuberculosis-infected guinea
pigs in comparison with that of DNA vaccine encoding
Ag85A,” Tuberculosis, vol. 87, no. 2, pp. 94–101, 2007.
[8] I. Sugawara, L. Sun, S. Mizuno, and T. Taniyama, “Protective
eﬃcacy of recombinant BCG Tokyo (Ag85A) in rhesus mon-
keys (Macaca mulatta) infected intratracheally with H37Rv
Mycobacterium tuberculosis,” Tuberculosis,v o l .8 9 ,n o .1 ,p p .
62–67, 2009.
[9] R. Jain, B. Dey, N. Dhar et al., “Enhanced and enduring pro-
tection against tuberculosis by recombinant BCG-Ag85C and
its association with modulation of cytokine proﬁle in lung,”
PLoS One, vol. 3, no. 12, Article ID e3869, 2008.
[10] A. S. Pym, P. Brodin, L. Majlessi et al., “Recombinant BCG
exporting ESAT-6 confers enhanced protection against tuber-
culosis,” Nature Medicine, vol. 9, no. 5, pp. 533–539, 2003.
[11] X.L.Fan,T.H.Yu,Q.Gao,andW.Yao,“Immunologicalprop-
erties of recombinant Mycobacterium bovis bacillus Calmette-
Gu´ erin strain expressing fusion protein IL-2-ESAT-6,” Acta
Biochimica et Biophysica Sinica, vol. 38, no. 10, pp. 683–690,
2006.
[12] L. M. Wang, C. H. Shi, X. L. Fan, Y. Xue, Y. L. Bai, and Z. K.
Xu, “Expression and immunogenicity of recombinant Myco-
bacterium bovis Bacillus Calmette-Gu´ erin strains secreting the
antigen ESAT-6 from Mycobacterium tuberculosis in mice,”
ChineseMedicalJournal,vol.120,no.14,pp.1220–1225, 2007.
[13] B. Dey, R. Jain, A. Khera et al., “Boosting with a DNA vac-
cine expressing ESAT-6 (DNAE6) obliterates the protection
imparted by recombinant BCG (rBCGE6) against aerosol My-
cobacterium tuberculosis infection in guinea pigs,” Vaccine, vol.
28, no. 1, pp. 63–70, 2009.
[14] C. Shi, L. Chen, Z. Chen et al., “Enhanced protection against
tuberculosis by vaccination with recombinant BCG over-
expressing HspX protein,” Vaccine, vol. 28, no. 32, pp. 5237–
5244, 2010.
[15] F. A. Mir, S. H. E. Kaufmann, and A. N. Eddine, “A multi-
cistronic DNA vaccine induces signiﬁcant protection against
tuberculosis in mice and oﬀers ﬂexibility in the expressed
antigen repertoire,” Clinical and Vaccine Immunology, vol. 16,
no. 10, pp. 1467–1475, 2009.
[ 1 6 ] S .C .D e r r i c k ,A .L .Y a n g ,a n dS .L .M o r r i s ,“ Ap o l y v a l e n tD N A
vaccine expressing an ESAT6-Ag85B fusion protein protects
mice against a primary infection with Mycobacterium tubercu-
losis and boosts BCG-induced protective immunity,” Vaccine,
vol. 23, no. 6, pp. 780–788, 2004.
[17] Y. A. W. Skeiky, M. R. Alderson, P. J. Ovendale et al., “Diﬀer-
ential immune responses and protective eﬃcacy induced by
components of a tuberculosis polyprotein vaccine, Mtb72F,
delivered as naked DNA or recombinant protein,” Journal of
Immunology, vol. 172, no. 12, pp. 7618–7628, 2004.
[18] J. Lu, C. Cai, C. Wang et al., “Immunogenicity and protective
eﬃcacy against murine tuberculosis of a prime-boost regimen
with BCG and a DNA vaccine expressing ESAT-6 and Ag85A
fusion protein,” Clinical and Developmental Immunology, vol.
2011, Article ID 617892, 10 pages, 2011.
[19] W. Yuan, N. Dong, L. Zhang et al., “Immunogenicity and
protective eﬃcacy of a tuberculosis DNA vaccine expressing
a fusion protein of Ag85B-Esat6-HspX in mice,” Vaccine, vol.
30, no. 14, pp. 2490–2497, 2012.
[20] Y. Q. Qie, J. L. Wang, B. D. Zhu et al., “Evaluation of a new
recombinant BCG which contains mycobacterial antigen
ag85B-mpt64190-198-mtb8.4 in C57/BL6 mice,” Scandina-
vian Journal of Immunology, vol. 67, no. 2, pp. 133–139, 2008.
[21] J.L.Wang,Y.Q.Qie,B.D.Zhuetal.,“Evaluationofarecombi-
nant BCG expressing antigen Ag85B and PPE protein Rv3425
from DNA segment RD11 of Mycobacterium tuberculosis in
C57BL/6 mice,” Medical Microbiology and Immunology, vol.
198, no. 1, pp. 5–11, 2009.
[22] Y.Q.Qie,J.L.Wang,W.Liuetal.,“Morevaccineeﬃcacystud-
ies on the recombinant bacille calmette-guerin co-expressing
Ag85B, Mpt64190-198 and Mtb8.4,” Scandinavian Journal of
Immunology, vol. 69, no. 4, pp. 342–350, 2009.
[23] H. Shen, C. Wang, E. Yang et al., “Novel recombinant BCG
coexpressing Ag85B, ESAT-6 and mouse TNF-α induces sig-
niﬁcantly enhanced cellular immune and antibody responses
in C57BL/6 mice,” Microbiology and Immunology, vol. 54, no.
8, pp. 435–441, 2010.Clinical and Developmental Immunology 9
[24] Y.Xu,B.Zhu,Q.Wangetal.,“RecombinantBCGcoexpressing
Ag85B, ESAT-6 and mouse-IFN-γ confers eﬀective protection
against Mycobacterium tuberculosis in C57BL/6 mice,” FEMS
Immunology and Medical Microbiology, vol. 51, no. 3, pp. 480–
487, 2007.
[25] Y. Xu, W. Liu, H. Shen, J. Yan, E. Yang, and H. Wang, “Recom-
binant Mycobacterium bovis BCG expressing chimaeric pro-
tein of Ag85B and ESAT-6 enhances immunostimulatory ac-
tivity of human macrophages,” Microbes and Infection, vol. 12,
no. 8-9, pp. 683–689, 2010.
[26] X. Fan, Q. Gao, and R. Fu, “Diﬀerential immunogenicity and
protective eﬃcacy of DNA vaccines expressing proteins of
Mycobacteriumtuberculosisinamousemodel,”Microbiological
Research, vol. 164, no. 4, pp. 374–382, 2009.
[27] P.E.M.Fine,“Variationinprotectionby BCG:implications of
andforheterologousimmunity,”Lancet,vol.346,no.8986,pp.
1339–1345, 1995.
[28] P. Andersen, “Tuberculosis vaccines—an update,” Nature Re-
views Microbiology, vol. 5, no. 7, pp. 484–487, 2007.
[29] M. Dennehy and A. L. Williamson, “Factors inﬂuencing the
immuneresponsetoforeignantigenexpressedinrecombinant
BCG vaccines,” Vaccine, vol. 23, no. 10, pp. 1209–1224, 2005.
[ 3 0 ]F .A .P o s t ,C .M a n c a ,O .N e y r o l l e s ,B .R y ﬀel, D. B. Young, and
G.Kaplan,“Mycobacteriumtuberculosis19-kilodaltonlipopro-
tein inhibits Mycobacterium smegmatis-induced cytokine pro-
duction by human macrophages in vitro,” Infection and Im-
munity, vol. 69, no. 3, pp. 1433–1439, 2001.
[31] V. Rao, N. Dhar, H. Shakila et al., “Increased expression of
Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the
protective eﬃcacy of BCG by polarizing host immune re-
sponses to the Th2 subtype,” Scandinavian Journal of Im-
munology, vol. 61, no. 5, pp. 410–417, 2005.
[32] A. H. Hovav, J. Mullerad, L. Davidovitch et al., “The Mycobac-
terium tuberculosis recombinant 27-kilodalton lipoprotein
induces a strong Th1-type immune response deleterious to
protection,” Infection and Immunity, vol. 71, no. 6, pp. 3146–
3154, 2003.
[33] A. Tanghe, O. Denis, B. Lambrecht, V. Motte, T. Van Den
Berg, and K. Huygen, “Tuberculosis DNA vaccine encoding
Ag85A is immunogenic and protective when administered by
intramuscular needle injection but not by epidermal gene gun
bombardment,” Infection and Immunity,v o l .6 8 ,n o .7 ,p p .
3854–3860, 2000.
[34] L. Bao, W. Chen, H. Zhang, and X. Wang, “Virulence, im-
munogenicity, and protective eﬃcacy of two recombinant
MycobacteriumbovisbacillusCalmette-Gu´ erinstrainsexpress-
ing the antigen ESAT-6 from Mycobacterium tuberculosis,”
Infection and Immunity, vol. 71, no. 4, pp. 1656–1661, 2003.
[35] A. S. Pym, P. Brodin, L. Majlessi et al., “Recombinant BCG
exporting ESAT-6 confers enhanced protection against tuber-
culosis,” Nature Medicine, vol. 9, no. 5, pp. 533–539, 2003.
[36] J. T. Belisle, V. D. Vissa, T. Sievert, K. Takayama, P. J. Brennan,
and G. S. Besra, “Role of the major antigen of Mycobacterium
tuberculosis in cell wall biogenesis,” Science, vol. 276, no. 5317,
pp. 1420–1422, 1997.
[ 3 7 ] J .L .F l y n n ,J .C h a n ,K .J .T r i e b o l d ,D .K .D a l t o n ,T .A .S t e w a r t ,
and B. R. Bloom, “An essential role for interferon γ in resis-
tance to Mycobacterium tuberculosis infection,” Journal of Ex-
perimental Medicine, vol. 178, no. 6, pp. 2249–2254, 1993.
[38] L. F. Barker, M. J. Brennan, P. K. Rosenstein, and J. C. Sadoﬀ,
“Tuberculosis vaccine research: the impact of immunology,”
Current Opinion in Immunology, vol. 21, no. 3, pp. 331–338,
2009.
[39] K. Dheda, S. K. Schwander, B. Zhu, R. N. Van Zyl-Smit, and
Y. Zhang, “The immunology of tuberculosis: from bench to
bedside,” Respirology, vol. 15, no. 3, pp. 433–450, 2010.